Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/hepr.70029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mac-2 Binding Protein Glycosylation Isomer as a Dynamic Biomarker in Obstructive Cholestasis.
Hepatol Res
August 2025
Department of Medicine, Division of Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan.
Expert consensus on clinical usefulness of M2BPGi for managing chronic liver diseases.
J Formos Med Assoc
August 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan; Grad
Chronic liver disease is a major global health concern, leading to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Accurate fibrosis staging is essential for clinical management, yet liver biopsy remains invasive. Non-invasive tools such as transient elastography and serum biomarkers provide alternatives, but conventional markers like APRI and FIB-4 have limitations.
View Article and Find Full Text PDFSerum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy.
JHEP Rep
September 2025
Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Background & Aims: Most patients with hepatocellular carcinoma (HCC) have underlying chronic liver disease, which may influence survival outcomes. Mac-2 binding protein glycosylation isomer (M2BPGi) is a biomarker reflecting liver fibrosis status, which in turn may be associated with survival in patients with HCC treated with immune checkpoint inhibitors (ICIs), particularly in regions where viral hepatitis is endemic.
Methods: From September 2017 to September 2022, 158 patients receiving ICIs for unresectable HCC were prospectively enrolled, and baseline serum samples were collected for M2BPGi measurement.
Analytical dissection of minor glycoforms and glycoprotein associations in rAAV preparations by multimodal glycoproteomics.
Anal Bioanal Chem
August 2025
Department of Biotechnology, Graduate School of Engineering, The University of Osaka, 2-1 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Accurate glycan analysis of viral vectors is essential for evaluating pharmaceutical quality. Recent advances in mass spectrometry-based analytical technologies have achieved glycosylation detection in adeno-associated viruses (AAVs). However, because only a minor subpopulation (< 1%) of recombinant AAV (rAAV) particles may carry glycans or associate with glycoproteins, distinguishing genuine AAV glycosylation from that of co-purified glycoproteins remains technically challenging, highlighting the need for analytical strategies that minimize glycan misassignment and reliably identify glycoprotein interactions.
View Article and Find Full Text PDFDifferential Effects of SGLT-2 Inhibitors on Liver Function and Nocturia in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Diabetes Metab Syndr Obes
July 2025
Department of Pharmacy, College of Pharmaceutical Science, Ritsumeikan University, Kusatsu, 807-8555, Japan.
Purpose: This study investigated whether sodium-glucose cotransporter-2 inhibitors (SGLT-2is) improve liver function as a class effect and evaluated their effect on nocturia in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD).
Methods: A total of 135 patients with type 2 diabetes and MASLD were randomly assigned to receive tofogliflozin (20 mg/day), dapagliflozin (5 mg/day), or empagliflozin (10 mg/day). Primary outcomes included changes in liver function and fibrosis markers-various transferases, fibrosis-4 index, mac-2 binding protein glycan isomer, and shear wave speed-along with nocturia frequency.